Management of patients with HBeAg-negative chronic hepatitis B.
Chronic hepatitis B (CHB) is one of the leading causes of morbidity and mortality worldwide. Although various drugs are available for the treatment of CHB, emergence of the hepatitis B e antigen (HBeAg)-negative mutant variant, specifically in Asia, the Middle East and southern Europe, is creating a new challenge as this variant is less responsive to available treatments. HBeAg-negative CHB rapidly progresses to cirrhosis and its related complications. This review discusses the available literature on the approved and under-trial treatment options and their respective efficacies for HBeAg-negative CHB.
Saikia
Nripen
N
Department of Gastroenterology, Pushpawati Singhania Research Institute, New Delhi, India. saikia.n@gmail.com
Talukdar
Rupjyoti
R
Mazumder
Subhasish
S
Khanna
Sudeep
S
Tandon
Rakesh
R
D000998:Antiviral Agents / Q000627:therapeutic use*; D005544:Forecasting; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy*; D006801:Humans
D000998:Antiviral Agents; D006513:Hepatitis B e Antigens